The document summarizes Profarma's earnings release for the second quarter of 2008.
- Profarma's gross revenue grew 21.8% year-over-year to R$742.8 million. Adjusted EBITDA grew 21.6% to R$23.9 million. Market share reached 11.8%, up 1.1 percentage points from the prior year.
- Branded products revenue grew 28.4% while generics grew 19.6% and OTC grew 9.5%. Operating expenses were 7.9% of net revenue. Net income grew to R$8.3 million.
- Cash flow from operating activities was negative R$24 million due to a R
The document summarizes Profarma's earnings results for the second quarter of 2008. Key highlights include a 21.8% increase in gross revenue compared to the same period last year, reaching R$742.8 million. Adjusted EBITDA grew 21.6% to R$23.9 million. Profarma's market share reached 11.8%, up 1.1 percentage points from the prior year.
- Profarma's consolidated gross revenue grew 26.5% year-over-year to R$702.6 million in 1Q08.
- The company's market share reached 11.8% in 1Q08, a 1.1 percentage point increase from the prior year.
- Adjusted EBITDA grew 24% to R$18.6 million compared to R$15 million in 1Q07.
The document reports on Profarma's financial results for the second quarter of 2007, highlighting revenue growth of 29.2% compared to the same period last year, driven by an acquisition. Adjusted EBITDA grew 16.8% to R$19.7 million in 2Q07. Profarma also saw increases in market share, gross profit margin, and operating expenses as a percentage of net revenue compared to prior periods.
Profarma's market share reached a record 12.0% in 3Q07, with gross revenues growing 31.9% to R$698.2 million compared to 3Q06. Net earnings increased 94.9% to R$8.2 million due to strong sales growth across branded, generic, and OTC products. Adjusted EBITDA was R$21.6 million for 3Q07, a 12.9% increase over 3Q06, demonstrating improved profitability.
- Profarma saw a 12.3% growth in consolidated gross revenue compared to the same period last year, reaching R$784 million, with strong growth in hospitals and vaccines.
- Operating expenses decreased 12.5% compared to the previous quarter, reaching their best level since 2004 at 7% of net revenue.
- Cash cycle was reduced by about six days, generating R$40 million in working capital reduction.
Profarma reported financial results for the first quarter of 2007, with highlights including:
- Gross revenue increased 26.8% year-over-year to R$555.3 million, driven by the opening of a new distribution center in Ceará and growth across all business segments.
- Adjusted EBITDA grew 17.8% to R$15 million compared to the first quarter of 2006.
- Net income increased 324.1% to R$5.1 million, compared to R$1.2 million in the prior year period.
- Key operating metrics such as service level, logistics productivity and sales per employee improved compared to the prior year, demonstrating strong operating execution
The document summarizes Profarma's earnings results for the second quarter of 2008. Key highlights include a 21.8% increase in gross revenue compared to the same period last year, reaching R$742.8 million. Adjusted EBITDA grew 21.6% to R$23.9 million. Profarma's market share reached 11.8%, up 1.1 percentage points from the prior year.
- Profarma's consolidated gross revenue grew 26.5% year-over-year to R$702.6 million in 1Q08.
- The company's market share reached 11.8% in 1Q08, a 1.1 percentage point increase from the prior year.
- Adjusted EBITDA grew 24% to R$18.6 million compared to R$15 million in 1Q07.
The document reports on Profarma's financial results for the second quarter of 2007, highlighting revenue growth of 29.2% compared to the same period last year, driven by an acquisition. Adjusted EBITDA grew 16.8% to R$19.7 million in 2Q07. Profarma also saw increases in market share, gross profit margin, and operating expenses as a percentage of net revenue compared to prior periods.
Profarma's market share reached a record 12.0% in 3Q07, with gross revenues growing 31.9% to R$698.2 million compared to 3Q06. Net earnings increased 94.9% to R$8.2 million due to strong sales growth across branded, generic, and OTC products. Adjusted EBITDA was R$21.6 million for 3Q07, a 12.9% increase over 3Q06, demonstrating improved profitability.
- Profarma saw a 12.3% growth in consolidated gross revenue compared to the same period last year, reaching R$784 million, with strong growth in hospitals and vaccines.
- Operating expenses decreased 12.5% compared to the previous quarter, reaching their best level since 2004 at 7% of net revenue.
- Cash cycle was reduced by about six days, generating R$40 million in working capital reduction.
Profarma reported financial results for the first quarter of 2007, with highlights including:
- Gross revenue increased 26.8% year-over-year to R$555.3 million, driven by the opening of a new distribution center in Ceará and growth across all business segments.
- Adjusted EBITDA grew 17.8% to R$15 million compared to the first quarter of 2006.
- Net income increased 324.1% to R$5.1 million, compared to R$1.2 million in the prior year period.
- Key operating metrics such as service level, logistics productivity and sales per employee improved compared to the prior year, demonstrating strong operating execution
1. The document reports key operational and financial results for 1Q08. Launchings increased 474.5% to R$410.2 million compared to 1Q07, with contracted sales up 651.5% to R$751.5 million.
2. Gross revenues increased 431.4% to R$245.1 million, net revenues increased 432% to R$133 million, and gross profits increased 904.6% to R$99.5 million compared to 1Q07.
3. EBITDA increased 3,053.9% to R$67.3 million and net income increased 680.1% to R$44.3 million compared to 1Q
Mariana Pereira
Address: Av. Brigadeiro Faria Lima,
3477 - 11th floor,
Ipanema, Rio de Janeiro,
RJ - Brazil - CEP 22430-000
NY Representative:
MZ Group - Greg Falesnik
Telephone: 1-949-385-6449
E-mail: greg.falesnik@mzgroup.us
Thank you for your interest in Profarma.
Please let us know if you need any
additional information.
Best regards,
Profarma Investor Relations
18
omnicom group Q3 2008 Investor Presentationfinance22
Omnicom Group presented financial results for the third quarter and year-to-date period ending September 30, 2008. Key highlights include:
- Revenue grew 6.9% in Q3 2008 and 10.1% year-to-date. Organic growth contributed 4.1% and 5.0% respectively.
- Net income increased 5.6% in Q3 2008 and 10.2% year-to-date. Earnings per share grew 11.3% and 15.0% respectively.
- Advertising and CRM were the largest disciplines by revenue, together accounting for over 80% of total revenue. The United States was the largest market by revenue at over
Embraer announced strong financial results for the second quarter of 2008, with net revenue increasing 21.9% and net income up 34.3% over the same period last year. The company also announced new executive jet models, received certifications, and signed new contracts. Looking forward, Embraer forecasts increased deliveries and continued growth, with planned investments in research and development as well as property, plant, and equipment.
Verizon held its 4th Quarter 2008 Earnings Conference Call on January 27, 2009. The document includes a safe harbor statement noting factors that could affect future results. It then summarizes key highlights from 2008 including earnings, cash flow, and dividend growth while continuing investment. For 4Q 2008 specifically, it notes revenue growth in strategic areas and customer growth, while acknowledging cyclical business impacts. Overall, it presents delivering solid results in a challenging environment.
1) Grocery operations continued to perform well with normalized EBIT up to €3.3 million.
2) The divestment of ABC is progressing as planned with signing targeted for late Q4.
3) Grocery revenue was up 14% and normalized EBIT increased 50% due to higher sales, margin growth, and lower marketing costs.
This document is a disclaimer for an investment presentation by Profarma. It states that the presentation does not constitute an offering or form the basis of any contract. The information provided should not be relied upon for investment decisions and contains forward-looking statements that are subject to risks. The document contains summary information that is not intended to be complete without additional context.
Localiza Rent a Car reported financial results for the first quarter of 2012 with several highlights:
- Revenue grew 16.4% compared to the first quarter of 2011 to R$774.7 million driven by a 17.8% increase in rental revenues.
- EBITDA increased 12.8% to R$210 million compared to the first quarter of 2011.
- Net income grew 14.3% to R$72.7 million compared to the first quarter of 2011.
The document provides an earnings release and financial highlights for 3Q14 of a Brazilian pharmaceutical company. It reported consolidated gross revenues growth of 7.2% year-over-year. The retail division saw an 83.3% increase in EBITDA at Drogasmil/Farmalife and 51.1% growth at Tamoio. Specialty retail sales increased 16.8% year-over-year and oncology sales grew 38%. Pharmaceutical distribution sales increased 7.8% with operating expenses falling 0.4 percentage points and branded category sales up 11.5%.
- The company reported a 13.3% growth in consolidated gross revenue in 2008 compared to the previous year, reaching R$2.9 billion, with significant growth in the vaccine and hospital segments.
- Operating expenses decreased 5% in 2008 compared to the previous year, reaching 7.6% of net revenue.
- The company reduced average accounts receivable terms for the fourth quarter in a row, decreasing working capital by R$50 million for the year.
Luciana Gomes
Phone: 55 (21) 4009 0276
E-mail: luciana.gomes@profarma.com.br
Address: Av. Brasil, 4.000 - Módulo 30
Rio de Janeiro, RJ - Brazil - 22031-915
Profarma's shares are traded on the São Paulo Stock Exchange (BOVESPA) under the ticker PFRA3.
The document summarizes Profarma's 3Q10 earnings release. Key highlights include:
- Revenues grew 11.8% quarter-over-quarter to R$809.8 million, with strong growth in health and beauty products of 34.3%.
- Operating cash flow was positive for the second consecutive quarter at R$62.1 million.
- The cash cycle improved to 48.8 days, the shortest since 2006, reducing working capital needs.
- Net debt fell 42.9% from the prior quarter to R$75.1 million, with the net debt to EBITDA ratio dropping to 0.8x.
Profarma's market share reached a record 12.0% in 3Q07, with gross revenues growing 31.9% to R$698.2 million compared to 3Q06. Net earnings increased 94.9% to R$8.2 million in 3Q07 versus the same period last year. Adjusted EBITDA was R$21.6 million in 3Q07, representing growth of 12.9% over 3Q06, as the company's operations and financial metrics improved across key areas.
- Net income rose 333.6% quarter-over-quarter to R$9.5 million, with a 1.4% net margin. Gross revenues grew 7.5% year-over-year to R$779.4 million.
- Sales of health and beauty products, which increased for the sixth quarter in a row, rose 87.3% year-over-year.
- Operating expenses fell 1.4 percentage points year-over-year to 7.5% of net operating revenue. Sales through electronic orders hit a record high of 68.6% of total sales.
- Profarma's consolidated gross revenue grew 26.5% year-over-year to R$702.6 million in 1Q08. Profarma's market share reached 11.8%, up 1.1 percentage points from 1Q07.
- Adjusted EBITDA grew 24% to R$18.6 million compared to R$15 million in 1Q07. Service levels reached 91.2%, up 1.2 percentage points from 1Q07.
- Average price increases were 3.1% in March 2008, 50% higher than the previous year. Branded revenues grew 34.5% to R$503 million, while generics revenues grew 2.8% to R$34 million
This earnings release from Profarma highlights their financial results for the second quarter of 2007, including revenue growth of 29.2% and net profit growth of 134.5%. A key event was the acquisition of Dimper's assets in Rio Grande do Sul for R$13.1 million, expanding their market share. Adjusted EBITDA grew 16.8% and their new Ceará branch achieved 5.9% market share, contributing to continued financial performance.
The document summarizes Profarma's financial and operational highlights for 3Q08. Key points include:
- 12.3% growth in gross revenue compared to 3Q07, reaching R$784 million, driven by strong hospital and vaccine sales.
- Reduced cash cycle by 6 days, generating R$40 million in working capital savings.
- Lower operating expenses of 7.0% of net revenue, the best since 2004, through a 12.5% reduction versus prior quarter.
- Market share reached 12.1%, up from 11.8% in 3Q07, demonstrating continued growth since the 2006 IPO.
- Profarma opened a new distribution center in Ceará, expanding its market reach and increasing its national market share.
- In Q1 2007, Profarma saw increases in gross revenue, adjusted EBITDA, and net income compared to Q1 2006.
- Key operating metrics like service level, logistics productivity, and sales per square meter also improved in Q1 2007 versus the previous year.
1. The document reports key operational and financial results for 1Q08. Launchings increased 474.5% to R$410.2 million compared to 1Q07, with contracted sales up 651.5% to R$751.5 million.
2. Gross revenues increased 431.4% to R$245.1 million, net revenues increased 432% to R$133 million, and gross profits increased 904.6% to R$99.5 million compared to 1Q07.
3. EBITDA increased 3,053.9% to R$67.3 million and net income increased 680.1% to R$44.3 million compared to 1Q
Mariana Pereira
Address: Av. Brigadeiro Faria Lima,
3477 - 11th floor,
Ipanema, Rio de Janeiro,
RJ - Brazil - CEP 22430-000
NY Representative:
MZ Group - Greg Falesnik
Telephone: 1-949-385-6449
E-mail: greg.falesnik@mzgroup.us
Thank you for your interest in Profarma.
Please let us know if you need any
additional information.
Best regards,
Profarma Investor Relations
18
omnicom group Q3 2008 Investor Presentationfinance22
Omnicom Group presented financial results for the third quarter and year-to-date period ending September 30, 2008. Key highlights include:
- Revenue grew 6.9% in Q3 2008 and 10.1% year-to-date. Organic growth contributed 4.1% and 5.0% respectively.
- Net income increased 5.6% in Q3 2008 and 10.2% year-to-date. Earnings per share grew 11.3% and 15.0% respectively.
- Advertising and CRM were the largest disciplines by revenue, together accounting for over 80% of total revenue. The United States was the largest market by revenue at over
Embraer announced strong financial results for the second quarter of 2008, with net revenue increasing 21.9% and net income up 34.3% over the same period last year. The company also announced new executive jet models, received certifications, and signed new contracts. Looking forward, Embraer forecasts increased deliveries and continued growth, with planned investments in research and development as well as property, plant, and equipment.
Verizon held its 4th Quarter 2008 Earnings Conference Call on January 27, 2009. The document includes a safe harbor statement noting factors that could affect future results. It then summarizes key highlights from 2008 including earnings, cash flow, and dividend growth while continuing investment. For 4Q 2008 specifically, it notes revenue growth in strategic areas and customer growth, while acknowledging cyclical business impacts. Overall, it presents delivering solid results in a challenging environment.
1) Grocery operations continued to perform well with normalized EBIT up to €3.3 million.
2) The divestment of ABC is progressing as planned with signing targeted for late Q4.
3) Grocery revenue was up 14% and normalized EBIT increased 50% due to higher sales, margin growth, and lower marketing costs.
This document is a disclaimer for an investment presentation by Profarma. It states that the presentation does not constitute an offering or form the basis of any contract. The information provided should not be relied upon for investment decisions and contains forward-looking statements that are subject to risks. The document contains summary information that is not intended to be complete without additional context.
Localiza Rent a Car reported financial results for the first quarter of 2012 with several highlights:
- Revenue grew 16.4% compared to the first quarter of 2011 to R$774.7 million driven by a 17.8% increase in rental revenues.
- EBITDA increased 12.8% to R$210 million compared to the first quarter of 2011.
- Net income grew 14.3% to R$72.7 million compared to the first quarter of 2011.
The document provides an earnings release and financial highlights for 3Q14 of a Brazilian pharmaceutical company. It reported consolidated gross revenues growth of 7.2% year-over-year. The retail division saw an 83.3% increase in EBITDA at Drogasmil/Farmalife and 51.1% growth at Tamoio. Specialty retail sales increased 16.8% year-over-year and oncology sales grew 38%. Pharmaceutical distribution sales increased 7.8% with operating expenses falling 0.4 percentage points and branded category sales up 11.5%.
- The company reported a 13.3% growth in consolidated gross revenue in 2008 compared to the previous year, reaching R$2.9 billion, with significant growth in the vaccine and hospital segments.
- Operating expenses decreased 5% in 2008 compared to the previous year, reaching 7.6% of net revenue.
- The company reduced average accounts receivable terms for the fourth quarter in a row, decreasing working capital by R$50 million for the year.
Luciana Gomes
Phone: 55 (21) 4009 0276
E-mail: luciana.gomes@profarma.com.br
Address: Av. Brasil, 4.000 - Módulo 30
Rio de Janeiro, RJ - Brazil - 22031-915
Profarma's shares are traded on the São Paulo Stock Exchange (BOVESPA) under the ticker PFRA3.
The document summarizes Profarma's 3Q10 earnings release. Key highlights include:
- Revenues grew 11.8% quarter-over-quarter to R$809.8 million, with strong growth in health and beauty products of 34.3%.
- Operating cash flow was positive for the second consecutive quarter at R$62.1 million.
- The cash cycle improved to 48.8 days, the shortest since 2006, reducing working capital needs.
- Net debt fell 42.9% from the prior quarter to R$75.1 million, with the net debt to EBITDA ratio dropping to 0.8x.
Profarma's market share reached a record 12.0% in 3Q07, with gross revenues growing 31.9% to R$698.2 million compared to 3Q06. Net earnings increased 94.9% to R$8.2 million in 3Q07 versus the same period last year. Adjusted EBITDA was R$21.6 million in 3Q07, representing growth of 12.9% over 3Q06, as the company's operations and financial metrics improved across key areas.
- Net income rose 333.6% quarter-over-quarter to R$9.5 million, with a 1.4% net margin. Gross revenues grew 7.5% year-over-year to R$779.4 million.
- Sales of health and beauty products, which increased for the sixth quarter in a row, rose 87.3% year-over-year.
- Operating expenses fell 1.4 percentage points year-over-year to 7.5% of net operating revenue. Sales through electronic orders hit a record high of 68.6% of total sales.
- Profarma's consolidated gross revenue grew 26.5% year-over-year to R$702.6 million in 1Q08. Profarma's market share reached 11.8%, up 1.1 percentage points from 1Q07.
- Adjusted EBITDA grew 24% to R$18.6 million compared to R$15 million in 1Q07. Service levels reached 91.2%, up 1.2 percentage points from 1Q07.
- Average price increases were 3.1% in March 2008, 50% higher than the previous year. Branded revenues grew 34.5% to R$503 million, while generics revenues grew 2.8% to R$34 million
This earnings release from Profarma highlights their financial results for the second quarter of 2007, including revenue growth of 29.2% and net profit growth of 134.5%. A key event was the acquisition of Dimper's assets in Rio Grande do Sul for R$13.1 million, expanding their market share. Adjusted EBITDA grew 16.8% and their new Ceará branch achieved 5.9% market share, contributing to continued financial performance.
The document summarizes Profarma's financial and operational highlights for 3Q08. Key points include:
- 12.3% growth in gross revenue compared to 3Q07, reaching R$784 million, driven by strong hospital and vaccine sales.
- Reduced cash cycle by 6 days, generating R$40 million in working capital savings.
- Lower operating expenses of 7.0% of net revenue, the best since 2004, through a 12.5% reduction versus prior quarter.
- Market share reached 12.1%, up from 11.8% in 3Q07, demonstrating continued growth since the 2006 IPO.
- Profarma opened a new distribution center in Ceará, expanding its market reach and increasing its national market share.
- In Q1 2007, Profarma saw increases in gross revenue, adjusted EBITDA, and net income compared to Q1 2006.
- Key operating metrics like service level, logistics productivity, and sales per square meter also improved in Q1 2007 versus the previous year.
Profarma's market share reached a record high of 12.8% in 4Q07, up from 9.6% in 2006. Consolidated gross revenue grew 40.1% compared to 4Q06, reaching R$740.4 million. Adjusted EBITDA was R$26.2 million, a 35.3% increase over 4Q06. New regions showed strong growth, with revenues of R$75 million, up 34.6% over 3Q07. The company reduced errors per million units shipped by 34.5% between 3Q07 and 4Q07.
Profarma's market share reached a record high of 12.8% in 4Q07, up from 9.6% in 2006. Consolidated gross revenue grew 40.1% compared to 4Q06, reaching R$740.4 million. Adjusted EBITDA was R$26.2 million, a 35.3% increase over 4Q06. New regions showed strong growth, with revenues of R$75 million, up 34.6% over 3Q07. The company's cash cycle improved to 64.3 days.
Profarma reported financial results for the first quarter of 2011, highlighting a 1.7% rise in consolidated gross revenues to R$778.8 million. The health and beauty products category saw strong sales growth of 78.0%. Operational efficiencies led to a 31.4% drop in logistics errors. However, net profit declined significantly to R$2.2 million due to higher operating expenses and financial costs. Cash flow from operations turned negative due to a large increase in working capital requirements.
- Profarma celebrated its 50th anniversary in May 2011 and reported a 1.7% rise in consolidated gross revenues compared to the previous year.
- The health and beauty products category saw strong sales growth of 78% year-over-year, while errors per million shipped units declined 31.4% from the prior year quarter.
- While most product categories saw revenue declines compared to the previous quarter, net profit decreased significantly from the prior quarter, dropping from R$10.5 million to R$2.2 million.
Paula Gomes
Phone: 55 (21) 4009 0276 ext. 8119
E-mail: paula.gomes@profarma.com.br
Address: Av. Brasil, 4.000 - Módulo 30
Rio de Janeiro, RJ
CEP: 22640-102
NY Representative:
MZ Group - Greg Falesnik
Phone: 1-949-385-6449
E-mail: greg.falesnik@mzgroup.us
This release contains forward-looking statements relating to the prospects of the business, estimates for operating and financial results, and those related to growth prospects of Profarma. These are merely projections
This document provides a summary of Profarma's 4Q10 and 2010 earnings release. Some key highlights include:
- A 3.7 day reduction in cash cycle compared to 2009, resulting in lower working capital of R$22.9 million
- Positive operating cash flow for the third consecutive year of R$44.4 million
- A 3.0% increase in consolidated gross revenues to R$3.1 billion in 2010
- Net debt decreased to R$108.7 million in December 2010
- The company reported a 3.7 day reduction in its cash cycle compared to 2009, lowering costs by R$22.9 million. Operating cash flow was positive for the third straight year at R$44.4 million.
- Gross revenues increased 3.0% to R$3.1 billion in 2010, with strong 37.8% growth in health and beauty products. Sales through electronic orders reached a record 65.3% of total sales.
- Net debt declined R$9.4 million to R$108.7 million in 2010 due to positive operating cash generation of R$44.4 million.
Profarma reported financial results for the first quarter of 2012, with the following highlights:
- Gross revenues increased 22.6% year-over-year to R$954.5 million.
- Net income increased 336.3% year-over-year to R$9.5 million, with a net margin of 1.2%.
- EBITDA increased 84.8% year-over-year to R$20.2 million, with an EBITDA margin of 2.5%.
- Tempo Assist saw growth in its health, dental, and assistance segments in 2009 through acquisitions and new partnerships.
- Key events included implementing SAP, rebranding as Tempo Assist, and receiving approval for its Unibanco Saúde acquisition.
- The segments achieved increased revenues and beneficiaries. Dental and health saw particularly strong growth while maintaining stable costs.
The company's net income increased 164.2% in 3Q09 compared to 3Q08, EBITDA increased 79.3%, and the cash cycle was reduced by 7.1 days. Gross revenues grew 3.2% and market share increased to 12.1%. Operating expenses declined 4.2% as a percentage of net revenues. The
- The company's net profit increased 47.1% compared to the previous quarter, reaching R$11.4 million.
- Inventory levels were reduced by 11.2 days compared to 1Q10.
- Cash flow from operating activities was positive at R$47.4 million.
- The ratio of net debt to EBITDA was reduced to 1.4x from 1.5x the previous quarter.
The document provides financial results and highlights for Profarma's 3Q12 earnings release. Key points include:
- Consolidated revenues grew 15.3% year-over-year to R$957.7 million.
- Net income increased 27.4% to R$10.8 million, with a net margin of 1.3%.
- EBITDA grew 14.7% to R$22.1 million and the EBITDA margin was 2.7%.
- Sales of generic medications increased 54.7% compared to 3Q11.
Similar to Earnings Release 2Q08 Presentation (19)
O documento fornece informações sobre a Profarma, incluindo sua história, estrutura organizacional, realizações recentes, planos de capitalização e sinergias entre suas divisões de distribuição e varejo. O documento também apresenta métricas financeiras e operacionais das principais aquisições da empresa.
- Profarma's 3Q17 earnings release discusses financial results, capital allocation strategy, and division performances. Key highlights include consolidated gross revenue growth of 4.5% and a shortened consolidated cash cycle. The Retail Division accounted for 55% of gross profit versus 40% in 3Q16. Pharma distribution sales decreased 6.6% year-over-year. Net income was adjusted for non-recurring expenses from restructuring. Capex was primarily for IT, machinery, and equipment while net debt declined.
O documento resume os principais resultados financeiros do 3T17 do Grupo Profarma. Destaca o crescimento de 4,5% na receita bruta consolidada, a redução de 16 dias no ciclo de caixa para 35 dias e o aumento da participação do varejo no lucro bruto consolidado para 55%. Também ressalta iniciativas de realocação de capital e redução de custos nas diversas divisões visando aumentar a rentabilidade.
The document provides financial information for Profarma's 2Q17 earnings release. Key highlights include:
- Consolidated sales grew 6.7% year-over-year led by 55.4% growth in retail sales.
- Pharma distribution sales increased 3.9% with 10% growth in independent customer segment. Cash cycle was shortened by 16.8 days.
- Specialties sales grew 3.6% in 1H17 year-over-year with vaccine sales up 40.2% and generics category up 6.3%. Operating expenses declined 0.3 percentage points.
- Retail EBITDA margin improved compared to prior periods through expense optimization initiatives.
O documento resume o desempenho financeiro da empresa no 2T17, com destaque para:
- Crescimento de 6,7% na receita total consolidada, impulsionada por alta de 55,4% no segmento varejo;
- Melhora no lucro líquido ajustado consolidado de R$2,9 milhões em relação ao trimestre anterior;
- Inauguração em setembro de um novo centro de distribuição no Rio de Janeiro, com investimento de R$40 milhões.
1. Profarma's consolidated sales grew 8.1% in 1Q17, driven by a 56.7% increase in retail sales. The pharma distribution division saw a 9.3% rise in gross profit and a 5% increase in EBITDA.
2. Specialties sales increased 12.8% in 1Q17, with operating expenses declining 1.2 percentage points. The independent customers segment in pharma distribution grew 19.9%.
3. The retail division saw gross margin increase 0.9 percentage points to 30.5% and adjusted EBITDA rise 17.1%. The Rosario stores reported a 75% increase in average monthly sales per store.
O documento resume o desempenho da empresa no 1T17, com crescimento de vendas de 8,1% e redução do endividamento. As principais divisões tiveram evolução nos indicadores, com destaque para o crescimento de 56,7% nas vendas do segmento varejo.
The document summarizes Profarma's capital allocation strategy and performance in 2016. In 2016, Profarma achieved gross revenues of R$5.5 billion, up 12.5% year-over-year. EBITDA was R$144.6 million with a margin of 2.6%. Acquisitions of Rosário and remaining stakes in other companies contributed to growth. The company's diversified business model across pharmaceutical distribution, retail drugstores, and specialty products enhances competitiveness and synergies.
Em 2011, a Companhia decidiu diversificar suas atividades para além da distribuição farmacêutica em busca de maiores retornos. Desde então, realizou várias aquisições de empresas de especialidades e varejo farmacêutico. Em 2016, adquiriu a Rosário, ampliando sua atuação no varejo.
The document summarizes financial information for a Brazilian pharmaceutical company for the third quarter of 2016. It reported consolidated gross revenues of R$1.367 billion for the quarter, a 3.7% increase year-over-year. The retail segment saw a 1.9% decrease in EBITDA compared to the previous year. Specialties sales increased 19.9% year-over-year while distribution sales grew 3.0%. The company's net debt to EBITDA ratio was 3.1x for the quarter.
O documento resume os resultados financeiros da Profarma no 3T16, destacando:
1) Crescimento de 3,7% na receita bruta consolidada em relação ao 3T15;
2) Aumento de 12,3% no lucro bruto da distribuição farmacêutica;
3) Incremento de 19,9% na receita bruta de especialidades e de 1,1 ponto percentual na margem bruta.
Esta apresentação descreve a aquisição da rede de farmácias Rosário pelo Grupo Profarma. A aquisição da rede líder na região Centro-Oeste por R$ 173 milhões permitirá ao Grupo Profarma expandir sua atuação no varejo farmacêutico e capturar sinergias operacionais.
Profarma is acquiring Drogaria Rosário for R$173 million. The acquisition will be paid through R$32 million in cash at closing and R$91 million 36 months after closing. The acquisition expands Profarma's retail footprint and positions its d1000 retail division as the 6th largest drugstore chain in Brazil. The acquisition offers synergies through increased scale and bargaining power. Profarma has a track record of successfully integrating and turning around acquisitions like Drogasmil/Farmalife. The Rosário acquisition strengthens Profarma's strategic positioning across multiple divisions.
The document summarizes Profarma's 2Q16 earnings release. Key highlights include:
- Consolidated pro-forma gross revenue increased 15.2% and EBITDA rose 59.8% to R$60.2 million.
- Retail sales grew 10.5% and EBITDA increased 50.1% to R$9.8 million. Specialties sales rose 41.9% and EBITDA grew 80% to R$5.1 million.
- Pharmaceutical distribution sales grew 11.4% and EBITDA increased 59% to R$45.1 million, the best performance in 7 years.
Este documento fornece um resumo dos resultados financeiros do 2T16. Destaca o crescimento de 15,2% na receita bruta consolidada e aumento de 59,8% no Ebitda consolidado. Também destaca o desempenho por divisão, com crescimento de vendas de 11,4% na Distribuição Farma, 41,9% nas Especialidades e 10,5% no Varejo.
Este documento apresenta uma análise da dinâmica positiva do setor farmacêutico global e brasileiro nos últimos anos. (1) O mercado global de medicamentos deve alcançar US$ 1,3 trilhões até 2018, impulsionado principalmente pelos mercados emergentes. (2) No Brasil, o mercado farmacêutico tem crescido acima do PIB nos últimos anos, apoiado por fatores demográficos e estruturais. (3) A distribuição e o varejo farmacêutico brasileiros também apresentaram forte
Este documento apresenta uma análise da dinâmica positiva do setor farmacêutico global e brasileiro nos últimos anos. (1) O gasto global com medicamentos deve alcançar US$ 1,3 trilhões até 2018, impulsionado principalmente pelos mercados emergentes. (2) No Brasil, o mercado farmacêutico tem crescido acima do PIB nos últimos anos, apoiado por fatores demográficos e econômicos. (3) A distribuição e o varejo farmacêutico brasileiros também apresentaram forte
O documento apresenta os resultados financeiros do primeiro trimestre de 2016 de uma empresa de distribuição farmacêutica. Destaca-se:
1) Crescimento de 16,9% na receita bruta consolidada;
2) Aumento de 31% no EBITDA consolidado, atingindo R$ 25,8 milhões;
3) Redução no ciclo de caixa consolidado para 32,9 dias.
The document provides an earnings release and financial highlights for Profarma's 1Q16 results. Some key points include:
- Gross revenue increased 16.9% to R$1.338 billion driven by growth across all divisions.
- Consolidated EBITDA rose 31.0% to R$25.8 million with an EBITDA margin of 2.2%.
- The pharmaceutical distribution division saw a 17.0% revenue increase and 16.5% EBITDA growth.
- Specialties revenue grew 38.8% and EBITDA rose 82.9%.
- Retail sales increased 12.4% while EBITDA grew 81.7% to R$3.5
O documento resume o desempenho financeiro da empresa no quarto trimestre e ano de 2015. A receita bruta consolidada cresceu 10,5% no ano, com destaque para o crescimento de vendas na divisão de especialidades de 25,9% e no varejo de 16,1%. O EBITDA consolidado aumentou 31,4% em 2015, atingindo R$ 114,7 milhões.
2. Highlights For The Period 2
• A growth of 21.8% of the consolidated Gross Revenue when compared to the same
period of the previous year, having reached R$ 742.8 million.
• The adjusted EBITDA was of R$ 23.9 million, a growth of 21.6% in relation to the one
registered in the 2Q07 of R$ 19.7 million.
• Profarma’s market share reached 11.8% in the 2Q08. 1.1 percentage point above the
one reached during the same period of the previous year.
• Profarma contracted the services of UBS Pactual S.A. bank, on May 29, 2008, to be the
market maker of its shares in order to promote their liquidity.
• Profarma opened on July, 14, 2008 its first exclusive distribution center for the hospital
and vaccine segment in São Paulo.
6. Gross Profit and Revenues 6
from Services to Suppliers
In R$ MM
10.8% and as % Net Revenues
10.7%
10.4%
10.5
7.4
7.0
55.7 58.9
50.0
2Q07 1Q08 2Q08
Gross Profit Revenues from Services to Suppliers Adjusted GP Margin (%)
7. Operating Expenses 7
7.9% 7.9% In R$ MM
and as % Net Revenues
7.8%
50.9
47.5
42.0
2Q07 1Q08 2Q08
EXPENSES: General and Administrative + Selling and Marketing + Logistics and Distribution
8. Net Financial Expenses 8
In R$ MM
1.4% and as % Net Revenues
0.9%
0.5%
9.1
5.6
2.8
2Q07 1Q08 2Q08
9. Net Income 9
1.6% In R$ MM
and as % Net Revenues
1.0%
0.8%
8.3
6.6
5.0
2Q07 1Q08 2Q08
10. Adjusted EBITDA and EBITDA Margin 10
In R$ MM
3.7% 3.7% and as % Net Revenues
3.1%
23.9
19.7
18.6
2Q07 1Q08 2Q08
12. Cash Cycle 12
3Q06 4Q06 1Q07 2Q07 3Q07 4Q07 1Q08 2Q08
Cash Cycle - Days * 49.3 53.4 62.5 69.6 67.8 64.3 68.8 67.2
Accounts Receivable (1) 45.2 50.0 54.6 53.1 50.9 51.7 50.7 49.2
Inventories (2) 33.1 44.7 43.4 47.2 41.3 48.6 47.9 45.7
Accounts Payable (3) 29.0 41.3 35.6 30.7 24.5 36.0 29.8 27.7
*Average
(1) Average of Gross Revenues in the Quarter
(2) Average of COGS in the Quarter
(3) Average of COGS in the Quarter
13. Indebtedness 13
In R$ MM
Net Debt (R$ MM) and Net Debt / Ebitda*
1.5 1.9
0.9
163.3
124.8
68.6
2Q07 1Q08 2Q08
* Ebitda = Accumulated last 12 months
14. Capex 14
In R$ MM
and as % Net Revenues
0.2% 0.5%
0.3%
3.1
2.1
1.2
2Q07 1Q08 2Q08
15. Operating Indicators 15
Service Level Logistics E.P.M
(units served / units requested) (Errors per Million)
92.8%
204.3
92.0%
91.2% 100.0 98.0
2Q07 1Q08 2Q08 2Q07 1Q08 2Q08
16. Share Performance 16
196 * 100 pts basis on 25/oct/2006
191
186
181
176
171
166
161
164
156
151
146
141
136 139
131
126
121
116
111
110
106
101
96
25- 9- 24- 9- 24- 8- 23- 7- 22- 9- 24- 8- 23- 8- 23- 7- 22- 7- 22- 6- 21- 5- 20- 5- 20- 4- 19- 4- 19- 3- 18- 2- 17- 3- 18- 2- 17- 2- 17- 1- 16- 30-
out nov nov dez dez jan jan fev fev mar mar abr abr mai mai jun jun jul jul ago ago set set out out nov nov dez dez jan jan fev fev mar mar abr abr mai mai jun jun jun
Ibovespa IGC Profarma
17. Analyst Coverage 17
Firm Analyst Recommendation
João Carlos dos Santos - Alexandre Pizano
55 11 2188-4282 / 4316 / 4024
Merril Lynch Buy
joaocarlos_santos@ml.com
alexandre_pizano@ml.com
Tufic Salem - Rafael Shin - Antonio Gonzalez
52 55 5283-8952 / 8969 / 3821
Credit Suisse tufic.salem@credit-suisse.com Buy
rafael.shin@credit-suisse.com
antonio.gonzalez@creditsuisse.com
Alan Cardoso
Prosper Corretora Fone: 55 21 2138-8465 Buy
alan.cardoso@bancoprosper.com.br
Renata Faber - Marcio Osako
Fone: 55 11 5029-4542 / 4650 Hold
Itau BBA
renata.faber@itau.com.br
marcio.osako@itau.com.br
18. 18
IR Contacts:
Max Fischer
CFO and IRO
Beatriz Diez
IR Coordenator
Phone.: 55 (21) 4009 0276
E-mail: ri@profarma.com.br
www.profarma.com.br/ir